Pearce A, Haas M, Viney R, Pearson SA, Haywood P, Brown C, et al. Incidence and severity of self-reported chemotherapy side effects in routine care: a prospective cohort study. Ganti AK, editor. PLoS One. 2017;12(10):e0184360. https://doi.org/10.1371/journal.pone.0184360 [cited 2019 Apr 12]. Available from.
CAS Article PubMed PubMed Central Google Scholar
Carlotto A, Hogsett VL, Maiorini EM, Razulis JG, Sonis ST. The economic burden of toxicities associated with Cancer treatment: review of the literature and analysis of nausea and vomiting, Diarrhoea, Oral Mucositis and Fatigue. Pharmacoeconomics. 2013;31(9):753–66.
Wagland R, Richardson A, Ewings S, Armes J, Lennan E, Hankins M, et al. Prevalence of cancer chemotherapy-related problems, their relation to health-related quality of life and associated supportive care: a cross-sectional survey. Support Care Cancer. 2016;24(12):4901–11.
Lorusso D, Bria E, Costantini A, Di Maio M, Rosti G, Mancuso A. Patients’ perception of chemotherapy side effects: expectations, doctor-patient communication and impact on quality of life - an Italian survey. Eur J Cancer Care. 2017;26(2):e12618.
Jacobs JM, Ream ME, Pensak N, Nisotel LE, Fishbein JN. Patient experiences with Oral chemotherapy: adherence, symptoms, and quality of life. J Natl Compr Cancer Netw. 2019;17(3):221–8.
Clarke G, Johnston S, Corrie P, Kuhn I, Barclay S. Withdrawal of anticancer therapy in advanced disease: a systematic literature review. BMC Cancer. 2015;15:892.
CAS PubMed PubMed Central Article Google Scholar
Mahr A, Golmard C, Pham E, Iordache L, Deville L, Faure P. Types, frequencies, and burden of nonspecific adverse events of drugs: analysis of randomized placebo-controlled clinical trials. Pharmacoepidemiol Drug Saf. 2017;26(7):731–41.
CAS PubMed Article Google Scholar
Barsky A, Saintfort R, Rogers M, Borus J. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;10(1):133–4.
Chvetzoff G, Tannock IF. Placebo effects in oncology. J Natl Cancer Inst. 2003;95(1):19–29.
CAS PubMed Article Google Scholar
Colagiuri B, Zachariae R. Patient expectancy and post-chemotherapy nausea: a meta-analysis. Ann Behav Med. 2010;40(1):3–14.
Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA. 2012;307(6):567–8. https://doi.org/10.1001/jama.2012.115%5Cn Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L364220204%5Cn. http://jama.ama-assn.org/content/307/6/567.full.pdf+html%5Cn. http://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=00987484&id=doi:.
Article PubMed PubMed Central Google Scholar
Benedetti F, Amanzio M, Vighetti S, Asteggiano G. The biochemical and neuroendocrine bases of the Hyperalgesic nocebo effect. J Neurosci. 2006;26(46):12014–22.
CAS PubMed PubMed Central Article Google Scholar
Blasini M, Corsi N, Klinger R, Colloca L. Nocebo and pain: an overview of the psychoneurobiological mechanisms. Pain Rep. 2017;2(2):e585.
PubMed PubMed Central Article Google Scholar
Myers MG, Cairns JA, Singer J. The consent form as a possible cause of side effects. Clin Pharmacol Ther. 1987;42(3):250–3.
CAS PubMed Article Google Scholar
Cocco G. Erectile dysfunction after therapy with metoprolol: the Hawthorne effect. Cardiology. 2009;112(3):174–7.
CAS PubMed Article Google Scholar
Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med. 2007;4(6):1708–12.
Rief W, Barsky AJ, Glombiewski JA, Nestoriuc Y, Gaesmer H, Braehler E. Assessing general side effects in clinical trials: reference data from the general population. Pharmacoepidemiol Drug Saf. 2011;20:405–15 Available from: http://eprints.dinus.ac.id/15172/1/jurnal_14778.pdf.
Petrie KJ, Rief W. Psychobiological mechanisms of placebo and nocebo effects: pathways to improve treatments and reduce side effects. Annu Rev Psychol. 2018;70(1):599–625.
Petrie KJ, Faasse K, Crichton F, Grey A. How common are symptoms? Evidence from a New Zealand national telephone survey. BMJ Open. 2014;4(6):e005374 [cited 2019 Apr 9]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24928596.
PubMed PubMed Central Article Google Scholar
Webster RK, Weinman J, Rubin GJ. Medicine-related beliefs predict attribution of symptoms to a sham medicine: a prospective study. Br J Health Psychol. 2018;23(2):436–54.
PubMed PubMed Central Article Google Scholar
Fletcher C, Wilson C, Hutchinson AD, Grunfeld EA. The relationship between anticipated response and subsequent experience of cancer treatment-related side effects: a meta-analysis comparing effects before and after treatment exposure. Cancer Treat Rev. 2018;68(June):86–93. https://doi.org/10.1016/j.ctrv.2018.06.009.
Sohl SJ, Schnur JB, Montgomery GH. A Meta-analysis of the relationship between response expectancies and Cancer treatment-related side effects. J Pain Symptom Manag. 2009;38(5):775–84.
Nestoriuc Y, von Blanckenburg P, Schuricht F, Barsky AJ, Hadji P, Albert US, et al. Is it best to expect the worst? Influence of patients’ side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study. Ann Oncol. 2016;27(10):1909–15.
CAS PubMed Article Google Scholar
Shedden-Mora MC, Pan Y, Heisig SR, von Blanckenburg P, Rief W, Witzel I, et al. Optimizing expectations about endocrine treatment for breast cancer: results of the randomized controlled psy-breast trial. Clin Psychol Europe. 2020;2(1):1–20.
Pan Y, Kinitz T, Stapic M, Nestoriuc Y. Minimizing drug adverse events by informing about the nocebo effect—an experimental study. Front Psychiatry. 2019;10(July):1–12.
Crichton F, Petrie KJ. Health complaints and wind turbines: the efficacy of explaining the nocebo response to reduce symptom reporting. Environ Res. 2015;140:449–55.
CAS PubMed Article Google Scholar
Miceli J, Geller D, Tsung A, Hecht CL, Wang Y, Pathak R, et al. Illness perceptions and perceived stress in patients with advanced gastrointestinal cancer. Psycho-Oncology. 2019;28(7):1513–9.
PubMed PubMed Central Article Google Scholar
van Gestel YRBM, Lemmens VEPP, de Hingh IHJT, Steevens J, Rutten HJT, Nieuwenhuijzen GAP, et al. Influence of comorbidity and age on 1-, 2-, and 3-month postoperative mortality rates in gastrointestinal Cancer patients. Ann Surg Oncol. 2013;20(2):371–80.
Miller SM. Monitoring versus blunting styles of coping with cancer influence the information patients want and need about their disease. Cancer. 1980;76(2):167–77.
Tanja Z, Nina H. Seite an Seite - eine gynäkologische Krebserkrankung in der Partnerschaft gemeinsam bewältigen: ein Ratgeber für Paare. Göttingen: Hogrefe; 2008. [cited 2019 Apr 2]. Available from: https://www.hogrefe.de/shop/seite-an-seite-eine-gynaekologische-krebserkrankung-in-der-partnerschaft-gemeinsam-bewaeltigen-65856.html
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of Cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.
CAS PubMed Article Google Scholar
Quidde J, Pan Y, Salm M, Hendi A, Nilsson S, Oechsle K, et al. Preventing adverse events of chemotherapy by educating patients about the nocebo effect (RENNO study) – study protocol of a randomized controlled trial with gastrointestinal cancer patients. BMC Cancer. 2018;18(1):1–8.
Abramson JH. WINPEPI (PEPI-for-windows): computer programs for epidemiologists. Epidemiol Perspect Innov. 2004;1(1):6.
PubMed PubMed Central Article Google Scholar
Schneider S, Moyer A, Knapp-Oliver S, Sohl S, Cannella D, Targhetta V. Pre-intervention distress moderates the efficacy of psychosocial treatment for cancer patients: a meta-analysis. J Behav Med. 2010;33(1):1–14.
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47.
Díaz-Rubio E, Tabernero J, Gómez-España A, Massutí B, Sastre J, Chaves M, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish cooperative group for the treatment of digestive tumors trial. J Clin Oncol. 2007;25(27):4224–30.
Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46.
CAS PubMed Article Google Scholar
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.
CAS PubMed Article Google Scholar
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.
CAS PubMed Article Google Scholar
National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version. 2010;4:03.
von Blanckenburg P, Schuricht F, Albert US, Rief W, Nestoriuc Y. Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. BMC Cancer. 2013;13:426.
留言 (0)